SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Biallelic NAA60 variants with impaired n-terminal acetylation capacity cause autosomal recessive primary familial brain calcifications.

Chelban, V; Aksnes, H; Maroofian, R; LaMonica, LC; Seabra, L; Siggervåg, A; Devic, P; Shamseldin, HE; Vandrovcova, J; Murphy, D; et al. Chelban, V; Aksnes, H; Maroofian, R; LaMonica, LC; Seabra, L; Siggervåg, A; Devic, P; Shamseldin, HE; Vandrovcova, J; Murphy, D; Richard, A-C; Quenez, O; Bonnevalle, A; Zanetti, MN; Kaiyrzhanov, R; Salpietro, V; Efthymiou, S; Schottlaender, LV; Morsy, H; Scardamaglia, A; Tariq, A; Pagnamenta, AT; Pennavaria, A; Krogstad, LS; Bekkelund, ÅK; Caiella, A; Glomnes, N; Brønstad, KM; Tury, S; Moreno De Luca, A; Boland-Auge, A; Olaso, R; Deleuze, J-F; Anheim, M; Cretin, B; Vona, B; Alajlan, F; Abdulwahab, F; Battini, J-L; İpek, R; Bauer, P; Zifarelli, G; Gungor, S; Kurul, SH; Lochmuller, H; Da'as, SI; Fakhro, KA; Gómez-Pascual, A; Botía, JA; Wood, NW; Horvath, R; Ernst, AM; Rothman, JE; McEntagart, M; Crow, YJ; Alkuraya, FS; Nicolas, G; SYNaPS Study Group; Arnesen, T; Houlden, H (2024) Biallelic NAA60 variants with impaired n-terminal acetylation capacity cause autosomal recessive primary familial brain calcifications. Nat Commun, 15 (1). p. 2269. ISSN 2041-1723 https://doi.org/10.1038/s41467-024-46354-0
SGUL Authors: McEntagart, Meriel

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (5MB) | Preview
[img]
Preview
PDF (Supplementary Information) Supplemental Material
Download (2MB) | Preview
[img]
Preview
PDF (Peer Review File) Supplemental Material
Available under License Creative Commons Attribution.

Download (576kB) | Preview
[img]
Preview
PDF (Description of Additional Supplementary Files) Supplemental Material
Download (91kB) | Preview
[img] Microsoft Excel (Supplementary Data 1) Supplemental Material
Download (32kB)
[img] Video (MP4) (Supplementary Movie 1Supplementary Movie 2) Supplemental Material
Download (191MB)
[img] Video (AVI) (Supplementary Movie 2) Supplemental Material
Download (216kB)
[img]
Preview
PDF (Reporting Summary) Supplemental Material
Download (3MB) | Preview
[img]
Preview
PDF (Reporting Summary old) Supplemental Material
Download (1MB) | Preview

Abstract

Primary familial brain calcification (PFBC) is characterized by calcium deposition in the brain, causing progressive movement disorders, psychiatric symptoms, and cognitive decline. PFBC is a heterogeneous disorder currently linked to variants in six different genes, but most patients remain genetically undiagnosed. Here, we identify biallelic NAA60 variants in ten individuals from seven families with autosomal recessive PFBC. The NAA60 variants lead to loss-of-function with lack of protein N-terminal (Nt)-acetylation activity. We show that the phosphate importer SLC20A2 is a substrate of NAA60 in vitro. In cells, loss of NAA60 caused reduced surface levels of SLC20A2 and a reduction in extracellular phosphate uptake. This study establishes NAA60 as a causal gene for PFBC, provides a possible biochemical explanation of its disease-causing mechanisms and underscores NAA60-mediated Nt-acetylation of transmembrane proteins as a fundamental process for healthy neurobiological functioning.

Item Type: Article
Additional Information: Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2024
Keywords: Humans, Acetylation, Brain, Brain Diseases, Inheritance Patterns, Mutation, Phosphates, Sodium-Phosphate Cotransporter Proteins, Type III, SYNaPS Study Group, Brain, Humans, Brain Diseases, Phosphates, Acetylation, Inheritance Patterns, Mutation, Sodium-Phosphate Cotransporter Proteins, Type III
Journal or Publication Title: Nat Commun
ISSN: 2041-1723
Language: eng
Dates:
DateEvent
13 March 2024Published
23 February 2024Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
221951/Z/20/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
MC_UU_00035/11Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
R35 GM142433NIGMS NIH HHSUNSPECIFIED
779257Horizon 2020http://dx.doi.org/10.13039/501100007601
MR/S01165X/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MR/S005021/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MRC ICGNMDMedical Research Councilhttp://dx.doi.org/10.13039/501100000265
540868Association of British NeurologistsUNSPECIFIED
565908Guarantors of Brainhttp://dx.doi.org/10.13039/501100000627
249843Research Council of NorwayUNSPECIFIED
Project F-12540Norwegian Health Authorities of Western NorwayUNSPECIFIED
171752—PR-2009-0222Norwegian Cancer SocietyUNSPECIFIED
772039Horizon 2020http://dx.doi.org/10.13039/501100007601
109915/Z/15/ZWellcome Trusthttp://dx.doi.org/10.13039/100004440
MR/N025431/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MR/V009346/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
309548European Research Councilhttp://dx.doi.org/10.13039/501100000781
MR/N027302/1Newton Fundhttp://dx.doi.org/10.13039/100010897
G100142Addenbrookes Charitable TrustUNSPECIFIED
UNSPECIFIEDNational Institute for Health and Care Researchhttp://dx.doi.org/10.13039/501100000272
UNSPECIFIEDNHS EnglandUNSPECIFIED
UNSPECIFIEDWellcome Trusthttp://dx.doi.org/10.13039/100004440
UNSPECIFIEDCancer Research UKhttp://dx.doi.org/10.13039/501100000289
UNSPECIFIEDMedical Research Councilhttp://dx.doi.org/10.13039/501100000265
UNSPECIFIEDNational Institute for Health Research University College London Hospitals Biomedical Research CenterUNSPECIFIED
UNSPECIFIEDRosetree TrustUNSPECIFIED
UNSPECIFIEDMSA TrustUNSPECIFIED
UNSPECIFIEDMSA CoalitionUNSPECIFIED
UNSPECIFIEDBrain Research UKhttp://dx.doi.org/10.13039/100013790
UNSPECIFIEDSparks GOSH CharityUNSPECIFIED
UNSPECIFIEDMuscular Dystrophy UKhttp://dx.doi.org/10.13039/100011724
UNSPECIFIEDEvelyn TrustUNSPECIFIED
UNSPECIFIEDStoneygate TrustUNSPECIFIED
UNSPECIFIEDLily FoundationUNSPECIFIED
MR/S005021/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
BRC-1215-20014NIHR Cambridge Biomedical Research Centrehttp://dx.doi.org/10.13039/501100018956
ANR-17-CE14–0008–02French National Research Agencyhttp://dx.doi.org/10.13039/501100001665
APERC 2014 no. 2014–19Conseil Régional de Haute Normandiehttp://dx.doi.org/10.13039/501100003191
UNSPECIFIEDRégion Normandie and the European UnionUNSPECIFIED
ANR-10-INBS-09Agence Nationale pour la RechercheUNSPECIFIED
ANR-17-CE14–0008–01French National Research Agencyhttp://dx.doi.org/10.13039/501100001665
ANR-10-IAHU-01French National Research AgencyUNSPECIFIED
469177153Deutsche Forschungsgemeinschafthttp://dx.doi.org/10.13039/501100001659
PubMed ID: 38480682
Web of Science ID: WOS:001228274200033
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/116732
Publisher's version: https://doi.org/10.1038/s41467-024-46354-0

Actions (login required)

Edit Item Edit Item